Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Monitoring the introduction of pneumococcal conjugate vaccines into West Africa: design and implementation of a population-based surveillance system.

Mackenzie GA, Plumb ID, Sambou S, Saha D, Uchendu U, Akinsola B, Ikumapayi UN, Baldeh I, Usuf E, Touray K, Jasseh M, Howie SR, Wattiaux A, Lee E, Knoll MD, Levine OS, Greenwood BM, Adegbola RA, Hill PC.

PLoS Med. 2012 Jan;9(1):e1001161. doi: 10.1371/journal.pmed.1001161. Epub 2012 Jan 17.

2.

Pneumococcal serotype evolution in Western Europe.

Tin Tin Htar M, Christopoulou D, Schmitt HJ.

BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x. Review.

3.

Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects.

Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL.

Vaccine. 2013 Dec 17;32(1):133-45. doi: 10.1016/j.vaccine.2013.05.005. Epub 2013 May 16. Review.

PMID:
23684824
4.

Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.

Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T.

Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320. Review.

5.

The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experience.

Madhi SA, Nunes MC.

Hum Vaccin Immunother. 2016;12(2):314-25. doi: 10.1080/21645515.2015.1084450. Review.

6.

Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis.

Balsells E, Guillot L, Nair H, Kyaw MH.

PLoS One. 2017 May 9;12(5):e0177113. doi: 10.1371/journal.pone.0177113. eCollection 2017. Review.

7.

Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.

Madhi SA, Cohen C, von Gottberg A.

Vaccine. 2012 Sep 7;30 Suppl 3:C21-7. doi: 10.1016/j.vaccine.2012.05.055. Review.

PMID:
22939016
8.

Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.

Dinleyici EC, Yargic ZA.

Expert Rev Vaccines. 2008 Nov;7(9):1367-94. doi: 10.1586/14760584.7.9.1367. Review.

PMID:
18980540
9.

Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L.

BMC Infect Dis. 2012 Sep 7;12:207. doi: 10.1186/1471-2334-12-207. Review.

10.

The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014.

Cohen R, Biscardi S, Levy C.

Hum Vaccin Immunother. 2016;12(2):277-84. doi: 10.1080/21645515.2015.1116654. Review.

11.

The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.

Giglio N, Micone P, Gentile A.

Vaccine. 2011 Sep 14;29 Suppl 3:C35-42. doi: 10.1016/j.vaccine.2011.06.095. Review.

PMID:
21896351
12.

Pneumococcal vaccination of older adults: conjugate or polysaccharide?

Fedson DS, Guppy MJ.

Hum Vaccin Immunother. 2013 Jun;9(6):1382-4. doi: 10.4161/hv.24692. Epub 2013 May 31. Review.

13.

Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake.

Grabenstein JD, Weber DJ.

Clin Infect Dis. 2014 Mar;58(6):854-64. doi: 10.1093/cid/cit800. Epub 2013 Dec 15. Review.

PMID:
24344141
14.

Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease.

Hausdorff WP, Dagan R, Beckers F, Schuerman L.

Vaccine. 2009 Dec 9;27(52):7257-69. doi: 10.1016/j.vaccine.2009.09.111. Epub 2009 Oct 13. Review.

PMID:
19833248
15.

New conjugate vaccines for the prevention of pneumococcal disease in developing countries.

Ginsburg AS, Alderson MR.

Drugs Today (Barc). 2011 Mar;47(3):207-14. doi: 10.1358/dot.2011.47.3.1556471. Review.

PMID:
21494698
17.
18.

Rationale and prospects for novel pneumococcal vaccines.

Moffitt K, Malley R.

Hum Vaccin Immunother. 2016;12(2):383-92. doi: 10.1080/21645515.2015.1087625. Review.

19.

The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease.

Principi N, Esposito S.

Expert Rev Vaccines. 2015;14(10):1359-66. doi: 10.1586/14760584.2015.1075884. Epub 2015 Aug 7. Review.

PMID:
26289973
20.

Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age.

Lucero MG, Dulalia VE, Nillos LT, Williams G, ParreƱo RA, Nohynek H, Riley ID, Makela H.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004977. doi: 10.1002/14651858.CD004977.pub2. Review.

PMID:
19821336

Supplemental Content

Support Center